Advertisement
Advertisement
U.S. Markets close in 5 hrs 34 mins
Advertisement
Advertisement
Advertisement
Advertisement

BRAIN Biotech AG (BNN.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
9.50-0.14 (-1.45%)
As of 02:58PM CET. Market open.
Advertisement

BRAIN Biotech AG

DarmstAedter Strasse 34-36
Zwingenberg 64673
Germany
49 62 51 9331 0
https://www.brain-biotech.de

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees297

Key Executives

NameTitlePayExercisedYear Born
Mr. Adriaan MoelkerChairman of the Management Board & CEO606.24kN/AN/A
Dr. Jurgen EckConsultant392kN/A1962
Mr. Ulrich PutschCo-FounderN/AN/AN/A
Mr. Lukas LinnigCFO & Member of Management BoardN/AN/A1993
Michael SchneidersHead of Investor RelationsN/AN/AN/A
Dr. Ute DechertVP of HR & ProcessesN/AN/A1961
Dr. Martin LangerExec. VP & Head of Bus. Devel.N/AN/A1965
Dr. Michael KrohnExec. VP and Head of R&DN/AN/A1963
Thomas DeichmannHead of PRN/AN/AN/A
Dr. Michael WaidelichHead of Skin Care Bus. UnitN/AN/A1975
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical and consumer goods industries in Germany, the United States, France, and the United Kingdom. The company operates through BioScience and BioIndustrial segments. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and natural-source substances for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.

Corporate Governance

BRAIN Biotech AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement